Effects of the Chinese herbal medicine Hong Huang decoction, on myocardial injury in breast cancer patients who underwent anthracycline-based chemotherapy

Sihan Cao; Jingxian Xue; Lu Chen; Yun Hao; Meijuan Lu; Ming Feng; Huanhuan Wang; Jun Zhou; Chang Yao

doi:10.3389/fcvm.2022.921753

Effects of the Chinese herbal medicine Hong Huang decoction, on myocardial injury in breast cancer patients who underwent anthracycline-based chemotherapy

Front Cardiovasc Med. 2022 Jul 22:9:921753. doi: 10.3389/fcvm.2022.921753. eCollection 2022.

Authors

Sihan Cao^{1

2}, Jingxian Xue¹, Lu Chen^{1

2}, Yun Hao^{1

2}, Meijuan Lu³, Ming Feng^{1

2}, Huanhuan Wang^{1

2}, Jun Zhou¹, Chang Yao¹

Affiliations

¹ Department of Breast Disease, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
² The First Clinical College, Nanjing University of Chinese Medicine, Nanjing, China.
³ Department of Echocardiography, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.

Abstract

Objective: To assess the effects of Hong Huang Decoction (HHD), a Chinese herbal medicine, on myocardial injury in breast cancer patients who underwent anthracycline (ANT)-based chemotherapy.

Methods: A total of 51 patients with breast cancer who underwent an ANT-based chemotherapy program and met the inclusion/exclusion criteria were allocated to the treatment or placebo groups using a random number generation process. Patients in the treatment group received liquid HHD twice a day. Treatment was given from 1 day prior to chemotherapy up to the end of chemotherapy (after 6 months). Participants in the placebo group received a placebo over the same schedule. Left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), diagnostic markers of acute myocardial infarction [e.g., lactate dehydrogenase (LDH), creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP)], nitric oxide (NO), superoxide dismutase (SOD), as well as pro-inflammatory cytokines [e.g., tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and human C-reactive protein (CRP)], and anti-inflammatory cytokine interleukin-10 (IL-10), were outcome measures assessed before chemotherapy, 3 and 6 months after chemotherapy.

Results: Compared to the placebo group, the GLS value was significantly higher in the treatment group (19.95 ± 1.16 vs. 19.06 ± 1.64, P ≤ 0.001). Significant differences were also noted for levels of SOD (689.71 ± 203.60 vs. 807.88 ± 182.10, P < 0.05), IL-6 (58.04 ± 22.06 vs. 194.20 ± 40.14, P ≤ 0.001), IL-10 (237.90 ± 94.98 vs. 68.81 ± 32.92, P ≤ 0.001), NO (75.05 ± 26.39 vs. 55.83 ± 19.37, P ≤ 0.005), and TNF-α (301.80 ± 134.20 vs. 680.30 ± 199.60, P ≤ 0.001) in the patients before chemotherapy compared to 6 months after initiating chemotherapy.

Conclusion: HHD regulated the levels of IL-6, IL-10, SOD, NO, and TNF-α. The results demonstrated that GLS is a better indicator of early myocardial injury compared to LVEF, and HHD could modulate oxidative stress to protect against ANT cardio toxicity.

Clinical trial registration: Chinese Clinical Trial Registry, identifier ChiCTR1900022394. Date of registration: 2019-04-09.

Keywords: GLS; Hong Huang decoction; anthracycline; breast cancer; chemotherapy.

Publication types

Case Reports